Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine

Van Den Borg, R; Leonetti, A; Tiseo, M; Giovannetti, E; Peters, GJ

Peters, GJ (reprint author), Vrije Univ Amsterdam Med Ctr, Amsterdam Univ Med Ctr, Dept Med Oncol, NL-1081 HV Amsterdam, Netherlands.

EXPERT REVIEW OF ANTICANCER THERAPY, 2019; 19 (6): 461

Abstract

Introduction: Small-cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumour, and its outcome is strongly conditioned by the rapid onset o......

Full Text Link